{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:48:03Z","timestamp":1790621283238,"version":"4.1.0"},"reference-count":33,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2016,9,8]],"date-time":"2016-09-08T00:00:00Z","timestamp":1473292800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"},{"start":{"date-parts":[[2016,9,8]],"date-time":"2016-09-08T00:00:00Z","timestamp":1473292800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions"}],"funder":[{"name":"Intramural Research Program of the Center for Cancer Research"},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Endocrinol"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1111\/cen.13154","type":"journal-article","created":{"date-parts":[[2016,7,9]],"date-time":"2016-07-09T08:32:58Z","timestamp":1468053178000},"page":"128-133","source":"Crossref","is-referenced-by-count":50,"title":["A phase II trial of valproic acid in patients with advanced, radioiodine-resistant thyroid cancers of follicular cell origin"],"prefix":"10.1111","volume":"86","author":[{"given":"Naris","family":"Nilubol","sequence":"first","affiliation":[{"name":"Endocrine Oncology Branch; National Cancer Institute; National Institutes of Health; Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxanne","family":"Merkel","sequence":"additional","affiliation":[{"name":"Endocrine Oncology Branch; National Cancer Institute; National Institutes of Health; Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily","family":"Yang","sequence":"additional","affiliation":[{"name":"Endocrine Oncology Branch; National Cancer Institute; National Institutes of Health; Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhaval","family":"Patel","sequence":"additional","affiliation":[{"name":"Endocrine Oncology Branch; National Cancer Institute; National Institutes of Health; Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department; Clinical Research Center; National Institutes of Health; Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira M.","family":"Sadowski","sequence":"additional","affiliation":[{"name":"Thoracic and Endocrine Surgery; University Hospitals of Geneva; Geneva Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Neychev","sequence":"additional","affiliation":[{"name":"Department of Surgery; University Multiprofile Hospital for Active Treatment \u2018Alexandrovska\u2019; Medical University; Sofia Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Electron","family":"Kebebew","sequence":"additional","affiliation":[{"name":"Endocrine Oncology Branch; National Cancer Institute; National Institutes of Health; Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,9,8]]},"reference":[{"key":"10.1111\/cen.13154-BIB0001|cen13154-cit-0001","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1001\/jama.295.18.2164","article-title":"Increasing incidence of thyroid cancer in the United States, 1973-2002","volume":"295","author":"Davies","year":"2006","journal-title":"JAMA"},{"key":"10.1111\/cen.13154-BIB0002|cen13154-cit-0002","first-page":"285","article-title":"Perspective: National cancer institute summary report about estimated exposures and thyroid doses received from iodine 131 in fallout after Nevada atmospheric nuclear bomb tests","volume":"48","author":"Hundahl","year":"1998","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.1111\/cen.13154-BIB0003|cen13154-cit-0003","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/bjs.1800800826","article-title":"Surgical reintervention for differentiated thyroid cancer","volume":"80","author":"Goretzki","year":"1993","journal-title":"British Journal of Surgery"},{"key":"10.1111\/cen.13154-BIB0004|cen13154-cit-0004","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1210\/jc.2005-2838","article-title":"Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy","volume":"91","author":"Durante","year":"2006","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1111\/cen.13154-BIB0005|cen13154-cit-0005","first-page":"1164","article-title":"Is empiric 131I therapy justified for patients with positive thyroglobulin and negative 131I whole-body scanning results?","volume":"46","author":"Ma","year":"2005","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1111\/cen.13154-BIB0006|cen13154-cit-0006","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1158\/1078-0432.CCR-08-1930","article-title":"Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I\/II trial of valproic acid and epirubicin\/FEC","volume":"15","author":"Munster","year":"2009","journal-title":"Clinical Cancer Research"},{"key":"10.1111\/cen.13154-BIB0007|cen13154-cit-0007","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/sj.bjc.6604817","article-title":"A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma","volume":"100","author":"Rocca","year":"2009","journal-title":"British Journal of Cancer"},{"key":"10.1111\/cen.13154-BIB0008|cen13154-cit-0008","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ctrv.2007.11.003","article-title":"Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors","volume":"34","author":"Duenas-Gonzalez","year":"2008","journal-title":"Cancer Treatment Reviews"},{"key":"10.1111\/cen.13154-BIB0009|cen13154-cit-0009","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.2174\/138161207782360528","article-title":"Valproic acid as anti-cancer drug","volume":"13","author":"Michaelis","year":"2007","journal-title":"Current Pharmaceutical Design"},{"key":"10.1111\/cen.13154-BIB0010|cen13154-cit-0010","first-page":"515","article-title":"Effects of the histone deacetylase inhibitor valproic acid on the sensitivity of anaplastic thyroid cancer cell lines to imatinib","volume":"21","author":"Catalano","year":"2009","journal-title":"Oncology Reports"},{"key":"10.1111\/cen.13154-BIB0011|cen13154-cit-0011","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1528-1167.2006.00953.x","article-title":"Endocrine effects of valproate in adolescent girls with epilepsy","volume":"48","author":"Vries","year":"2007","journal-title":"Epilepsia"},{"key":"10.1111\/cen.13154-BIB0012|cen13154-cit-0012","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1677\/joe.1.06970","article-title":"Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells","volume":"191","author":"Catalano","year":"2006","journal-title":"Journal of Endocrinology"},{"key":"10.1111\/cen.13154-BIB0013|cen13154-cit-0013","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.surg.2005.09.019","article-title":"Valproic acid inhibits growth, induces apoptosis, and modulates apoptosis-regulatory and differentiation gene expression in human thyroid cancer cells","volume":"138","author":"Shen","year":"2005","journal-title":"Surgery"},{"key":"10.1111\/cen.13154-BIB0014|cen13154-cit-0014","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1210\/jc.2004-1355","article-title":"Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells","volume":"90","author":"Catalano","year":"2005","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1111\/cen.13154-BIB0015|cen13154-cit-0015","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1210\/jc.2003-031407","article-title":"Valproic acid induces the expression of the Na+\/I- symporter and iodine uptake in poorly differentiated thyroid cancer cells","volume":"89","author":"Fortunati","year":"2004","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1111\/cen.13154-BIB0016|cen13154-cit-0016","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1111\/cen.13154-BIB0017|cen13154-cit-0017","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/RLU.0b013e318266d4d8","article-title":"Focus on high-risk DTC patients: high postoperative serum thyroglobulin level is a strong predictor of disease persistence and is associated to progression-free survival and overall survival","volume":"38","author":"Piccardo","year":"2013","journal-title":"Clinical Nuclear Medicine"},{"key":"10.1111\/cen.13154-BIB0018|cen13154-cit-0018","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1089\/thy.2012.0099","article-title":"One month is sufficient for urinary iodine to return to its baseline value after the use of water-soluble iodinated contrast agents in post-thyroidectomy patients requiring radioiodine therapy","volume":"22","author":"Padovani","year":"2012","journal-title":"Thyroid"},{"key":"10.1111\/cen.13154-BIB0019|cen13154-cit-0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"10.1111\/cen.13154-BIB0020|cen13154-cit-0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Controlled Clinical Trials"},{"key":"10.1111\/cen.13154-BIB0021|cen13154-cit-0021","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1212\/WNL.57.3.445","article-title":"Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy","volume":"57","author":"Sato","year":"2001","journal-title":"Neurology"},{"key":"10.1111\/cen.13154-BIB0022|cen13154-cit-0022","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/1471-2105-13-212","article-title":"Screening of selective histone deacetylase inhibitors by proteochemometric modeling","volume":"13","author":"Wu","year":"2012","journal-title":"BMC Bioinformatics"},{"key":"10.1111\/cen.13154-BIB0023|cen13154-cit-0023","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1200\/JCO.2005.14.167","article-title":"Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer","volume":"23","author":"Kelly","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/cen.13154-BIB0024|cen13154-cit-0024","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1210\/jc.2008-1631","article-title":"Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma","volume":"94","author":"Woyach","year":"2009","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1111\/cen.13154-BIB0025|cen13154-cit-0025","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1089\/thy.2012.0393","article-title":"Evaluation of romidepsin for clinical activity and radioactive iodine reuptake in radioactive iodine-refractory thyroid carcinoma","volume":"23","author":"Sherman","year":"2013","journal-title":"Thyroid"},{"key":"10.1111\/cen.13154-BIB0026|cen13154-cit-0026","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1210\/jcem.87.4.8373","article-title":"Lack of impact of radioiodine therapy in tg-positive, diagnostic whole-body scan-negative patients with follicular cell-derived thyroid cancer","volume":"87","author":"Fatourechi","year":"2002","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1111\/cen.13154-BIB0027|cen13154-cit-0027","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1007\/s00259-011-1849-2","article-title":"Combined therapy with 131I and retinoic acid in Korean patients with radioiodine-refractory papillary thyroid cancer","volume":"38","author":"Oh","year":"2011","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"key":"10.1111\/cen.13154-BIB0028|cen13154-cit-0028","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1056\/NEJMoa1209288","article-title":"Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer","volume":"368","author":"Ho","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"10.1111\/cen.13154-BIB0029|cen13154-cit-0029","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1210\/jc.2015-3433","article-title":"Robust thyroid gene expression and radioiodine uptake induced by simultaneous suppression of BRAF V600E and histone deacetylase in thyroid cancer cells","volume":"101","author":"Cheng","year":"2016","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1111\/cen.13154-BIB0030|cen13154-cit-0030","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1089\/thy.2006.16.1025","article-title":"Defective efficacy of retinoic acid treatment in patients with metastatic thyroid carcinoma","volume":"16","author":"Courbon","year":"2006","journal-title":"Thyroid"},{"key":"10.1111\/cen.13154-BIB0031|cen13154-cit-0031","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.clon.2004.06.018","article-title":"A phase II study using retinoids as redifferentiation agents to increase iodine uptake in metastatic thyroid cancer","volume":"16","author":"Short","year":"2004","journal-title":"Clinical Oncology"},{"key":"10.1111\/cen.13154-BIB0032|cen13154-cit-0032","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.semcancer.2006.09.005","article-title":"Thioredoxin in cancer-role of histone deacetylase inhibitors","volume":"16","author":"Marks","year":"2006","journal-title":"Seminars in Cancer Biology"},{"key":"10.1111\/cen.13154-BIB0033|cen13154-cit-0033","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/B978-0-12-394387-3.00002-1","article-title":"Mechanisms of resistance to histone deacetylase inhibitors","volume":"116","author":"Lee","year":"2012","journal-title":"Advances in Cancer Research"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcen.13154","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcen.13154","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/cen.13154\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T17:32:21Z","timestamp":1625419941000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cen.13154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,8]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"URL":"https:\/\/doi.org\/10.1111\/cen.13154","archive":["Portico"],"relation":{},"ISSN":["0300-0664"],"issn-type":[{"value":"0300-0664","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9,8]]}}}